Tumor cell PD-L1 expression is a strong predictor of unfavorable prognosis in immune checkpoint therapy-naive clear cell renal cell cancer.
Immune checkpoint therapy
PD-L1
Prognosis
Renal cell carcinoma
Journal
International urology and nephrology
ISSN: 1573-2584
Titre abrégé: Int Urol Nephrol
Pays: Netherlands
ID NLM: 0262521
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
received:
05
02
2021
accepted:
17
03
2021
pubmed:
3
4
2021
medline:
17
2
2022
entrez:
2
4
2021
Statut:
ppublish
Résumé
PD-L1 expression predicts response to immune checkpoint inhibitors in renal cell carcinomas (RCC), but has also been suggested to be linked to poor patient outcome. We analyzed PD-L1 in > 1400 RCC in a tissue microarray format by immunohistochemistry. Results were compared with histological tumor type, parameters of cancer aggressiveness, and intratumoral CD8 At a cut-off level of 5% PD-L1 positive tumor cells, PD-L1 positivity was seen in 6.3% of 633 clear cell RCC (ccRCC), 18.2% of 165 papillary RCC, 18.8% of 64 chromophobe RCC, and 41.7% of 103 oncocytomas. In ccRCC, PD-L1 positivity was significantly linked to high ISUP (p < 0.0001), Fuhrman (p < 0.0001), Thoenes grade (p < 0.0001), distant metastasis (p = 0.0042), short recurrence-free (p < 0.0001), and overall survival (p = 0.0002). Intratumoral CD8 These data suggest that PD-L1 expression in highly immunogenic RCCs facilitates immune evasion and contributes to cancer aggressiveness.
Sections du résumé
BACKGROUND
BACKGROUND
PD-L1 expression predicts response to immune checkpoint inhibitors in renal cell carcinomas (RCC), but has also been suggested to be linked to poor patient outcome.
METHODS
METHODS
We analyzed PD-L1 in > 1400 RCC in a tissue microarray format by immunohistochemistry. Results were compared with histological tumor type, parameters of cancer aggressiveness, and intratumoral CD8
RESULT
RESULTS
At a cut-off level of 5% PD-L1 positive tumor cells, PD-L1 positivity was seen in 6.3% of 633 clear cell RCC (ccRCC), 18.2% of 165 papillary RCC, 18.8% of 64 chromophobe RCC, and 41.7% of 103 oncocytomas. In ccRCC, PD-L1 positivity was significantly linked to high ISUP (p < 0.0001), Fuhrman (p < 0.0001), Thoenes grade (p < 0.0001), distant metastasis (p = 0.0042), short recurrence-free (p < 0.0001), and overall survival (p = 0.0002). Intratumoral CD8
CONCLUSIONS
CONCLUSIONS
These data suggest that PD-L1 expression in highly immunogenic RCCs facilitates immune evasion and contributes to cancer aggressiveness.
Identifiants
pubmed: 33797012
doi: 10.1007/s11255-021-02841-7
pii: 10.1007/s11255-021-02841-7
pmc: PMC8599390
doi:
Substances chimiques
B7-H1 Antigen
0
Biomarkers, Tumor
0
CD274 protein, human
0
Immune Checkpoint Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2493-2503Informations de copyright
© 2021. The Author(s).
Références
Am J Clin Pathol. 2019 Jan 7;151(2):217-225
pubmed: 30346474
World J Urol. 2021 Feb;39(2):481-490
pubmed: 32303902
N Engl J Med. 2019 Mar 21;380(12):1116-1127
pubmed: 30779529
Med Oncol. 2016 Jul;33(7):80
pubmed: 27317388
Ann Surg Oncol. 2016 Feb;23(2):694-702
pubmed: 26464193
BMC Urol. 2017 Jan 13;17(1):8
pubmed: 28086852
Sci Rep. 2017 May 18;7(1):2074
pubmed: 28522811
Cell Oncol (Dordr). 2020 Jun;43(3):421-430
pubmed: 32141029
J BUON. 2019 Jul-Aug;24(4):1644-1651
pubmed: 31646820
Clin Cancer Res. 2019 Oct 15;25(20):6080-6088
pubmed: 31371341
J Immunother Cancer. 2020 Jan;8(1):
pubmed: 31959726
Cancer Sci. 2019 Jun;110(6):1820-1828
pubmed: 30972888
Diagn Pathol. 2015 Oct 15;10:189
pubmed: 26470780
Clin Chem. 2019 Oct;65(10):1228-1238
pubmed: 31315901
J Immunother Cancer. 2020 Jul;8(2):
pubmed: 32661118
Transl Oncol. 2020 Feb;13(2):336-345
pubmed: 31881506
Cancer Immunol Immunother. 2020 Oct;69(10):2041-2051
pubmed: 32424467
Appl Immunohistochem Mol Morphol. 2020 Mar;28(3):213-220
pubmed: 31058656
Cancer Sci. 2019 May;110(5):1564-1572
pubmed: 30861269
Urol Int. 2020;104(7-8):533-541
pubmed: 32623437
Front Oncol. 2019 Apr 16;9:264
pubmed: 31058078
Nat Med. 1998 Jul;4(7):844-7
pubmed: 9662379
Cancer Med. 2020 Feb;9(3):1152-1160
pubmed: 31829518
Clin Genitourin Cancer. 2020 Aug;18(4):314-321.e1
pubmed: 32482565
Int J Clin Exp Pathol. 2015 Jul 01;8(7):8227-35
pubmed: 26339391
J Gastrointest Cancer. 2020 Jun;51(2):611-619
pubmed: 31028537
Diagn Pathol. 2018 Aug 25;13(1):60
pubmed: 30144808
Int J Mol Sci. 2017 Oct 20;18(10):
pubmed: 29053609
Ann Oncol. 2020 Aug;31(8):1030-1039
pubmed: 32339648
Histopathology. 2020 Feb;76(3):423-432
pubmed: 31494951
Ther Adv Urol. 2019 Oct 13;11:1756287219882600
pubmed: 31662794
Cancer Immunol Res. 2015 Dec;3(12):1303-7
pubmed: 26307625
Front Oncol. 2019 Nov 25;9:879
pubmed: 31824835
J Natl Cancer Inst. 2015 Feb 03;107(3):
pubmed: 25650315
Histopathology. 2020 Apr;76(5):714-721
pubmed: 31841221
Nature. 2015 Jan 1;517(7532):109-10
pubmed: 25557714
J Immunother Cancer. 2020 Mar;8(1):
pubmed: 32221016
Ann Oncol. 2014 Nov;25(11):2178-2184
pubmed: 25193987
PLoS One. 2017 Jun 27;12(6):e0179610
pubmed: 28654655
Cancer Immunol Res. 2015 Oct;3(10):1158-64
pubmed: 26014095
Asian Pac J Cancer Prev. 2019 Oct 01;20(10):2951-2957
pubmed: 31653140
Front Oncol. 2019 May 28;9:439
pubmed: 31192136
Eur Urol. 2019 May;75(5):799-810
pubmed: 30803729
Med Oncol. 2016 Nov;33(11):120
pubmed: 27696122
Cancers (Basel). 2020 Mar 20;12(3):
pubmed: 32245016
Clin Genitourin Cancer. 2019 Apr;17(2):97-104.e1
pubmed: 30522901
J Clin Oncol. 2011 May 20;29(15):1949-55
pubmed: 21483002
J Cancer. 2020 Mar 26;11(12):3596-3603
pubmed: 32284756
Hum Pathol. 2020 Jul;101:31-39
pubmed: 32360490
Am J Pathol. 2001 Dec;159(6):2249-56
pubmed: 11733374
Immunity. 2013 Jul 25;39(1):1-10
pubmed: 23890059
Dis Colon Rectum. 2019 Apr;62(4):498-508
pubmed: 30844974
Eur J Cancer. 2018 Nov;103:287
pubmed: 30270112
Urol Oncol. 2018 Dec;36(12):531.e19-531.e25
pubmed: 30322727
Clin Cancer Res. 2017 Aug 1;23(15):4416-4428
pubmed: 28213366
Clin Cancer Res. 2017 Jul 15;23(14):3847-3858
pubmed: 28108544
J Kidney Cancer VHL. 2018 Oct 13;5(4):6-13
pubmed: 30386718
Nature. 2017 Jan 18;541(7637):321-330
pubmed: 28102259
J Clin Pathol. 2020 Aug;73(8):463-469
pubmed: 31980560
Cancer Res. 2006 Apr 1;66(7):3381-5
pubmed: 16585157
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Clin Oncol. 2008 Nov 10;26(32):5233-9
pubmed: 18809613
Hum Immunol. 2018 Jun;79(6):446-452
pubmed: 29544815
Md Med J. 1988 Jul;37(7):547-50
pubmed: 3173001
Front Immunol. 2019 Mar 19;10:453
pubmed: 30941125